COMMUNIQUÉS West-GlobeNewswire

TerrAscend Announces Results of Special Meeting of Shareholders
25/08/2026
TORONTO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis operator, today announced the results of its special meeting of [...]
Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics
25/08/2026
Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on [...]
Moderna and Merck Cancer Vaccine Success Is Good News for CancerVax
24/08/2026
Positive topline results from Phase 3 trial of personalized cancer vaccine for melanoma de-risk LNP-mRNA therapies such as CancerVax Lehi, Utah, Aug. 24, 2026 (GLOBE NEWSWIRE) -- CancerVax, Inc. , the developer of a [...]
Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories
24/08/2026
CHICAGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced it is projecting Oliv18™ to [...]
Belite Bio to Host Virtual Commercial Day on September 2, 2026
24/08/2026
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
R3 Vascular Expands Management Team with Two Senior Executives
24/08/2026
Appointments Support Accelerated Trial Enrollment, Market Development, Scalability, and Future Commercialization MOUNTAIN VIEW, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company [...]
Seek Labs and NAMRU EURAFCENT Enter CRADA to Evaluate Field-Deployable Diagnostics for Infectious Diseases
24/08/2026
SALT LAKE CITY, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Seek Labs, a private TechBio company building programmable platforms to decode, program, and resolve diseases, today announced a Cooperative Research and Development [...]
InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved
24/08/2026
BEIJING, Aug. 24, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the interim results and business [...]
Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)
24/08/2026
Company announcement No. 41 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 34, 2026) Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: [...]
Zealand Pharma – Notification of holding of treasury shares
24/08/2026
Company announcement – No. 42 / 2026 Zealand Pharma – Notification of holding of treasury shares Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 34 - 2026
24/08/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 17 au 21 août 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2026
24/08/2026
Aggregated presentation by day and by market Weekly report on share repurchases from 17 th to 21 st August 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument [...]
Ozari Health Offers Compounded Semaglutide From $86 Per Month and Tirzepatide From $125 Per Month on Nationwide Telehealth Platform as Updated 2026 GLP-1 Pricing Data Goes Live
24/08/2026
LegitScript-certified platform connects patients with licensed providers for GLP-1 weight management, with all-in pricing, no membership fees, and no long-term contracts, and publishes an open dataset comparing real [...]
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
24/08/2026
Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise ZURICH, SWITZERLAND, and MARTINSRIED [...]
Mesoblast Financial Results and Corporate Update Webcast
24/08/2026
NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and [...]
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
24/08/2026
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages
24/08/2026
Company intends to accelerate the rehabilitation of Canndoc’s flagship Nir Oz facility, supporting a return to full production and the Company’s expansion in the growing German medical cannabis market NEW YORK and [...]
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
24/08/2026
Topline 26-week primary endpoint data from COVALENT-211 in insulin deficient type 2 diabetes (“T2D”) patients who are not achieving glycemic targets despite antihyperglycemic medications anticipated in the first quarter [...]
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
24/08/2026
BOSTON and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]

Pages